The scope of mycoplasma contamination within the biopharmaceutical industry

Area of Science:

• Biopharmaceutical Manufacturing
• Microbiology
• Cell Culture Technology

Background:

• Mycoplasma is a prevalent microbial contaminant in biopharmaceutical production, identified as early as 1956.
• Contamination rates in cell cultures range from 15-35%, with higher rates in specific populations.
• Recent advancements include the development of rapid microbiological methods for mycoplasma detection.

Purpose of the Study:

• To determine current mycoplasma infection levels in cell cultures, substrates, and biologicals within a client-based population.
• To retrospectively compare the performance of four different analytical assays for mycoplasma detection.
• To establish reference data for evaluating new rapid microbiological methods.

Main Methods:

• Retrospective analysis of 40,000 client-submitted samples.
• Comparison of results from four distinct analytical assays for mycoplasma detection.
• Data compilation to determine overall contamination rates.

Main Results:

• Analysis of 40,000 samples to establish current mycoplasma contamination rates.
• Comparative performance data for four analytical assays.
• Identification of reference contamination levels for method validation.

Conclusions:

• Establishing current contamination rates is crucial for critically appraising rapid microbiological methods.
• Understanding prevalence aids in the validation and implementation of effective mycoplasma detection strategies.
• Accurate mycoplasma detection is vital for biopharmaceutical quality and safety.